Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-04-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2010.02.057PMID 20211219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Papillomaviruses in the causation of human cancers - a brief historical account.

  2009cited by this paper
• Evaluation of interferences between dengue vaccine serotypes in a monkey model.

  2009cited by this paper
• A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.

  2008cited by this paper
• Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis

  2008cited by this paper
• HPV Vaccines: today and in the Future.

  2008cited by this paper
• Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

  2008cited by this paper
• HPV and cervical cancer in the 2007 report.

  2007cited by this paper
• Multiple whole bacterial antigens in polyvalent vaccine may result in inhibition of specific responses in rainbow trout (Oncorhynchus mykiss).

  2007cited by this paper
• Combined single‐clade candidate HIV‐1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference

  2007cited by this paper
• Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

  2007cited by this paper
• Human papillomavirus type distribution in women from Asia: a meta-analysis

  2007cited by this paper
• Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions

  2007cited by this paper
• Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines

  2007cited by this paper
• Encapsidating artificial human papillomavirus‐16 mE7 protein in human papillomavirus‐6b L1/L2 virus like particles

  2007cited by this paper
• Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.

  2007cited by this paper
• Prophylactic DNA immunization against multiple papillomavirus types.

  2007cited by this paper
• Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.

  2007cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31

  2006cited by this paper
• Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.

  2005cited by this paper
• CD4+ T cells cross‐compete for MHC class II‐restricted peptide antigen complexes on the surface of antigen presenting cells

  2004cited by this paper
• Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

  2004cited by this paper
• Reduced immunogenicity of DNA vaccine plasmids in mixtures

  2004cited by this paper
• Efficient Intracellular Assembly of Papillomaviral Vectors

  2004cited by this paper
• Expression of human papillomavirus type 6 L1 and L2 isolated in China and self assembly of virus-like particles by the products.

  2003cited by this paper
• Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer

  2002cited by this paper
• Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

  2002cited by this paper
• The Role of T Cell Antagonism and Original Antigenic Sin in Genetic Immunization1

  2002cited by this paper
• Papillomavirus Pseudovirus: a Novel Vaccine To Induce Mucosal and Systemic Cytotoxic T-Lymphocyte Responses

  2001cited by this paper
• Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus‐like particles in South African women with cervical cancer and cervical intraepithelial neoplasia

  2000cited by this paper
• Seroresponses to virus‐like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San People of Southern Africa

  2000cited by this paper
• Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.

  1999cited by this paper
• Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine.

  1999cited by this paper
• Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.

  1999cited by this paper
• Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

  1998cited by this paper
• Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants

  1998cited by this paper
• Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine

  1996cited by this paper
• Immunological parameters associated with antigenic competition in a multivalent footrot vaccine.

  1995cited by this paper
• Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

  1995cited by this paper
• Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

  1995cited by this paper
• Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation.

  1995cited by this paper
• Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination.

  1994cited by this paper
• Antigenic competition in a multivalent foot rot vaccine.

  1994cited by this paper
• Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein.

  1994cited by this paper
• Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

  1994cited by this paper
• Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

  1994cited by this paper
• Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

  1994cited by this paper
• Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

  1993cited by this paper
• The effects of antigenic competition on the efficacy of multivalent footrot vaccines.

  1993cited by this paper
• Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

  1992cited by this paper
• Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children

  1992cited by this paper
• Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins.

  1991cited by this paper
• Antigenic competition between dengue and Coxsackie viruses for presentation to B cells by macrophages.

  1990cited by this paper
• Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

  1990cited by this paper
• Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine.

  1988cited by this paper
• Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine.

  1988cited by this paper

• Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial

  2025cites this paper
• A lef5-deficient baculovirus expression system with no virion contamination and promoting secretion.

  2023cites this paper
• Immunogenicity of Multi-Target Chimeric RHDV Virus-like Particles Delivering Foreign B-Cell Epitopes

  2022cites this paper
• Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70

  2022cites this paper
• Combined Truncations at both N- and C-terminus of Human Papillomavirus Type 58 L1 Enhanced the Yield of Virus-like Particles Produced in a Baculovirus System.

  2021cites this paper
• Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines

  2021cites this paper
• Induction of cross‐neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines

  2020cites this paper
• Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles

  2020cites this paper
• A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.

  2019cites this paper
• Purification and characterization of immunogenic recombinant virus-like particles of porcine circovirus type 2 expressed in silkworm pupae.

  2018cites this paper
• Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum.

  2018cites this paper
• Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections

  2018cites this paper
• Broadly protective nanoparticle-based mucosal vaccine against influenza virus infection

  2018cites this paper
• Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice

  2018cites this paper
• A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model

  2017cites this paper
• Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types

  2017cites this paper
• Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.

  2016cites this paper
• Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.

  2016cites this paper
• Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.

  2016cites this paper
• Controlled Hybrid-Assembly of HPV16/18 L1 Bi VLPs in Vitro.

  2016cites this paper
• Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: Type‐specific prevalence and HPV coinfections

  2015cites this paper
• Prevalencia de genotipos de VPH en México y en el mundo detectados mediante Linear Array

  2015cites this paper
• Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice

  2015cites this paper
• Observations on the expression of human papillomavirus major capsid protein in HeLa cells

  2015cites this paper
• A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Cross-Neutralizing Antibodies and Protective Immunity against Divergent Human Papillomavirus Types

  2014influential citation
• Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens

  2014cites this paper
• Immunogenicity of a Trivalent Human Papillomavirus L1 DNA-Encapsidated, Non-Replicable Baculovirus Nanovaccine

  2014cites this paper
• Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model

  2014cites this paper
• Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

  2014cites this paper
• Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune Responses

  2014cites this paper
• Genome- and proteome-wide screening strategies for antigen discovery and immunogen design.

  2014cites this paper
• New approaches for the diagnosis of human papillomavirus infection:relevance for clinical practice and cancer prevention

  2014cites this paper
• Mechanisms of GII.4 norovirus antigenic variation and evolution

  2014cites this paper
• Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice

  2014cites this paper
• Broadly Blocking Immune Responses Virus-Like-Particle-Based Vaccines Induce Chimeric GII . 4 Norovirus

  2014cites this paper
• The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization

  2013cites this paper
• MULTIVALENT STRATEGIES AGAINST VIRUS PATHOGENS

  2013cites this paper
• Assessment of BTV VP7-169 as a vector for the display of foreign peptides

  2013cites this paper
• Preparation and Application of Neutralizing Monoclonal Antibodies Against Human Papillomavirus Type 58

  2012cites this paper
• A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

  2012cites this paper
• Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies

  2012influential citation
• The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae

  2012cites this paper
• Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

  2012cites this paper
• Insect cell technology is a versatile and robust vaccine manufacturing platform

  2011cites this paper
• Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

  2011cites this paper
• CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells

  2011cites this paper
• Simple and convenient chromatography-based methods for purifying the pseudovirus of human papillomavirus type 58.

  2011cites this paper
• Oncoprevention in gynecology.

  2010cites this paper
• Implementation of prophylactic HPV vaccination: Progress and future challenges

  2010cites this paper